26,635 Shares in AstraZeneca PLC (NASDAQ:AZN) Bought by Financial Gravity Asset Management Inc.

Financial Gravity Asset Management Inc. acquired a new position in AstraZeneca PLC (NASDAQ:AZN - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 26,635 shares of the company's stock, valued at approximately $1,958,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Parr Mcknight Wealth Management Group LLC grew its stake in AstraZeneca by 19.6% in the first quarter. Parr Mcknight Wealth Management Group LLC now owns 31,155 shares of the company's stock worth $2,290,000 after purchasing an additional 5,107 shares in the last quarter. Main Street Research LLC purchased a new stake in AstraZeneca during the first quarter worth $14,885,000. Nisa Investment Advisors LLC lifted its holdings in AstraZeneca by 115.4% during the first quarter. Nisa Investment Advisors LLC now owns 1,400 shares of the company's stock worth $103,000 after buying an additional 750 shares during the period. Axxcess Wealth Management LLC lifted its holdings in AstraZeneca by 6.0% during the first quarter. Axxcess Wealth Management LLC now owns 21,615 shares of the company's stock worth $1,589,000 after buying an additional 1,221 shares during the period. Finally, Rehmann Capital Advisory Group lifted its holdings in AstraZeneca by 5.3% during the first quarter. Rehmann Capital Advisory Group now owns 11,290 shares of the company's stock worth $830,000 after buying an additional 570 shares during the period. Institutional investors own 20.35% of the company's stock.

Wall Street Analysts Forecast Growth

AZN has been the subject of a number of analyst reports. Berenberg Bank set a $97.00 target price on AstraZeneca in a report on Wednesday. BNP Paribas initiated coverage on AstraZeneca in a report on Tuesday, April 15th. They set an "outperform" rating and a $75.00 target price for the company. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $89.00.

AstraZeneca Stock Down 0.9%

Shares of AstraZeneca stock traded down $0.68 during trading on Friday, reaching $71.13. The company's stock had a trading volume of 2,729,851 shares, compared to its average volume of 5,279,228. The company has a quick ratio of 0.70, a current ratio of 0.90 and a debt-to-equity ratio of 0.65. The company has a market cap of $220.60 billion, a price-to-earnings ratio of 28.57, a P/E/G ratio of 1.32 and a beta of 0.37. AstraZeneca PLC has a 1-year low of $61.24 and a 1-year high of $87.68. The company has a 50-day simple moving average of $70.72 and a two-hundred day simple moving average of $70.78.

AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The company reported $1.24 earnings per share for the quarter, topping analysts' consensus estimates of $1.10 by $0.14. The firm had revenue of $13.59 billion during the quarter, compared to analysts' expectations of $13.71 billion. AstraZeneca had a return on equity of 33.14% and a net margin of 14.14%. The business's quarterly revenue was up 7.2% on a year-over-year basis. During the same quarter last year, the firm earned $2.06 EPS. As a group, equities analysts forecast that AstraZeneca PLC will post 4.51 earnings per share for the current year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.